PDF(Sci-hub)
Abstract：
Nebivolol (N) is a β1-adrenoreceptor antagonist that is approved for treatment of hypertension in the USA. Effective treatment of hypertension is becoming an increasingly difficult process that often requires multiple drug combinations to meet target guidelines. This has resulted in the increasing introduction of multidrug single-pill combinations (SPCs) to facilitate cost and compliance issues. Some of the SPCs have added valsartan (V), an angiotensin receptor blocker, which is an increasingly advocated antihypertensive class. Pharmacological profiles of N and V, alone and combined, are well characterized. In 2007, the SPC of N and V, 5 and 80 mg, respectively, was approved by the US FDA for treatment of hypertension. This paper will summarize and update key issues in pharmacology, clinical use and benefit.
摘要：
奈比洛尔（N）是β1-肾上腺素受体拮抗剂，在美国被批准用于治疗高血压。高血压的有效治疗正变得越来越困难，通常需要多种药物组合来满足目标指南。这导致越来越多地引入多药单药组合(SPC)以促进成本和依从性问题。一些SPC添加了缬沙坦（V），血管紧张素受体阻滞剂,这是一个越来越提倡的抗高血压类。N和V的药理学概况，单独和组合，很好的特点。2007年，N和V的SPC，5和80毫克，分别,被美国FDA批准用于治疗高血压。本文将总结和更新药理学中的关键问题，临床使用和效益。
